Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Boardroom

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

- PMLiVE

Roche gets wider approval for haemophilia drug Hemlibra

Approved to treat bleeding episodes in patients without inhibitors

- PMLiVE

Encouraging data for Roche flu drug ahead of FDA decision

Trial looks at benefts in high risk groups

Roche Basel Switzerland

Roche drug hits the mark in spinal muscular atrophy studies

Data suggests Risdiplam could improve motor function

- PMLiVE

Roche’s Tecentriq misses survival mark in frontline NSCLC

Keytruda proving hard to beat

- PMLiVE

Labour party divided on Brexit ‘People’s Vote’

Growing support for second referendum being resisted by party leaders

- PMLiVE

Gilead and Galapagos JAK contender scores in RA trial

Trial adds to rivalry with AbbVie

Roche Basel Switzerland

Dismay as NICE rejects Roche’s MS drug Ocrevus

Treatment deemed too costly to treat primary progressive MS

- PMLiVE

Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

The latest industry movers

Gilead Sciences

Gilead, Galapagos JAK inhibitor clears phase II test

Hopes to compete with already-marketed drugs from Pfizer and Eli Lilly

- PMLiVE

Roche highlights Hemlibra data as key FDA date approaches

Expanded use would see revenues take off

Roche Basel Switzerland

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Deal is latest in series of big pharma investments in cancer immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links